published meta-analysis   sensitivity analysis   studies

ivermectin in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsKirti, 2021 0.12 [0.01; 2.36] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] 0.21[0.02; 2.19]Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 202120%264moderatenot evaluable clinical deteriorationdetailed resultsRIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95] 0.53[0.15; 1.95]RIVET-COV (Mohan) (12mg and 24mg), 202110%125NAnot evaluable clinical improvement (7-day)detailed resultsKirti, 2021 0.90 [0.77; 1.06] 0.90[0.77; 1.06]Kirti, 202110%112NAnot evaluable hospital dischargedetailed resultsKirti, 2021 1.20 [0.73; 1.98] RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04] 1.31[0.83; 2.09]Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 202120%237moderatenot evaluable mechanical ventilationdetailed resultsKirti, 2021 0.20 [0.00; 8.69] RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] 0.32[0.02; 4.80]Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 202120%264moderatenot evaluable viral clearance detailed resultsChaccour, 2020 0.92 [0.77; 1.09] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39] 0.93[0.78; 1.10]Chaccour, 2020, RIVET-COV (Mohan) (12mg and 24mg), 202120%138lownot evaluable viral clearance (time to event analysis only)detailed resultsAhmed, 2020 4.10 [1.12; 14.99] 4.10[1.12; 14.99]Ahmed, 202010%72NAnot evaluable viral clearance by day 14detailed resultsAhmed, 2020 4.10 [1.12; 14.99] 4.10[1.12; 14.99]Ahmed, 202010%72NAnot evaluable viral clearance by day 7detailed resultsChaccour, 2020 0.92 [0.77; 1.09] Kirti, 2021 0.80 [0.43; 1.50] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39] 0.92[0.78; 1.08]Chaccour, 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 202130%250lownot evaluable ICU admissiondetailed resultsKirti, 2021 0.90 [0.30; 2.70] 0.90[0.30; 2.70]Kirti, 202110%112NAnot evaluable serious adverse eventsdetailed resultsRIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47] 0.52[0.01; 26.47]RIVET-COV (Mohan) (12mg and 24mg), 202110%152NAnot evaluable adverse eventsdetailed resultsChaccour, 2020 1.00 [0.20; 5.07] RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47] 1.17[0.49; 2.78]Chaccour, 2020, RIVET-COV (Mohan) (12mg and 24mg), 202120%176moderatenot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-05-07 23:27 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 684,886 - roots T: 290